Objectives

After participating in this educational activity, attendees should be able to:

1. Review the general diagnosis and management of diabetic ketoacidosis (DKA)
2. Explain the mechanism of euglycemic diabetic ketoacidosis (euDKA) and its management.
3. Describe the mechanism by which SGLT2-inhibitors cause euDKA and precautions that should be taken in patients taking these agents

Clare Cycz, PharmD

PGY1 Pharmacy Resident
Pharmacist
Baystate Medical Center

Faculty Disclosure

The design and content of Baystate Continuing Interprofessional Education ( CE ) activities support quality improvement in healthcare and provide fair and balanced views of therapeutic options.  Faculty or planner conflicts of interest are resolved before the educational activity.

None of the members of the faculty and planning committee for this educational event have commercial relationships with any entity producing, marketing, re-selling or distributing health care goods and services consumed by or used on patients.